Kornimate/medical-research-clean huggingface dataset:
strength training and stroke

Conditions: Stroke

Summary: people with stroke experience weakness and incoordination. studies have shown that with functional task practice, people can increase motor control and strength to a certain extent. this study will investigate whether adding progressive resistance strength training to functional task practice modeled after constraint-induced movement therapy results in greater motor function gains than functional task practice alone

to date most investigations of ue rehabilitation have examined single interventions. however, combining 2 efficacious interventions may enhance effectiveness. both functional task training and strength training are beneficial for promoting improved upper extremity function, but they have seldom been studied as a coupled therapy. the research proposed in this project will examine the effect on ue function of adding ue resistive exercises to functional task training. secondary aims are to examine the effect of stroke severity on the response to therapy, the interrelationship between therapy-induced neural changes and movement composition and functional changes with therapy, and test for retention of ue function gains over 6 months. individuals with chronic hemiparesis from stroke will complete baseline testing and then be randomly assigned to either the functional task + strength training group or the functional task training alone group. each group will train 4 hours/day, 3 days/week for 4 weeks. each will perform 3 hours of functional task training per session. the strengthening group will then complete 1 hour of ue progressive resistance exercises while the functional task training alone group will complete gravity eliminated range of motion exercises for 1 hour. all subjects will be post-tested and then complete follow-up testing 6 months later.

Eligibility criteria:
inclusion criteria: 1. age 40-85; 2. a single unilateral middle cerebral artery ischemic stroke; 3. no history of drug/alcohol abuse; 4. ability to follow 3-step commands and provide informed consent; 5. no history of other neural disorder/dysfunction (including epilepsy), no serious medical illness or refractory depression; 6. at least 300 active upper extremity elevation in scapular plane (combination of flexion and abduction); 7. ability to extend the wrist 20 degrees, and two fingers and thumb 10 degrees three times in a minute; 8. permission of physician (brrc medical director or brrc neurologist) to participate in strength training. exclusion criteria: 1. spasticity in elbow or hand (modified ashworth scale \> 2); 2. motor activity log32 scores \>3 (which would indicate relatively good use of the upper extremity); 3. ability to complete 135 degrees shoulder elevation easily with elbow straight (e.g., doesn't hold breath, movement is fluid, little to no effort tremor observed); 4. ataxia, major sensory deficits, or hemi-inattention/neglect;

Keywords: rehabilitation upper extremity motor skills
evaluation of cardiotoxic effects of bortezomib

Conditions: Multiple Myeloma; Heart Failure, Systolic; Cardiotoxins

Summary: the purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart. in this study, the investigators will learn whether a drug called how a drug (called bortezomib, or velcade) receive for multiple myeloma affects the heart. bortezomib is part of the standard treatment and its effects on multiple myeloma is not being studied here. the investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple myeloma * have a treatment plan involving greater than 4 cycles of bortezomib-based chemotherapy exclusion criteria: * pre-existing history of left ventricular systolic dysfunction * congestive heart failure * coronary artery disease * significant valvular heart disease * cardiac arrhythmias * estimated glomerular filtration rate \<30 ml/min/1.73m2
ozone plasma on lung function and inflammatory parameters in pulmonary sequelae associated with coronavirus 19 infection

Conditions: COVID-19

Summary: the risk for the development of complications from covid-19 occurs mainly in patients over 65 years of age, with obesity, arterial hypertension, chronic lung diseases and immunosuppression states. since the persistence of radiological imaging correlates with physiological deterioration, these patients are likely to be at increased risk of parenchymal lung disease. it is known that the administration of ozone, in any of the three phases of covid-19 infection, is useful in the management of acute disease, both for its viricidal and anti-inflammatory activity, however, in the convalescence stage when the persistence of sequelae that can severely affect the quality of life of patients is identified.

the objective of this study is to evaluate whether the administration by inhalation of ozone plasma favorably modifies lung function and inflammatory parameters in patients with pulmonary sequelae associated with coronavirus 19 infection (sars-cov-2). we will conduct an open-ended, uncontrolled clinical trial in 35 male and female patients, between 25-80 years of age with previous confirmed diagnosis of covid-19 infection with negative nasopharyngeal polymerase chain reaction assay (pcr) test and without active disease, patients will also continue with their usual treatment. clinical findings and laboratory and cabinet tests include a basal and 14-day metabolic and inflammatory profile, body weight, body mass index (bmi) and blood pressure will be determined during the initial and final visit, as well as respiratory parameters by pulmonary function tests (spirometry, tlco) and performing the 6 min walk test in endless band with pre- and post-walk oximetry measurements at the beginning and end of the study. adverse events to treatment will be documented. statistical analysis: mann-whitney u test and wilcoxon exact test. a p \<0.05 shall be considered statistically significant.

Eligibility criteria:
inclusion criteria: * men and women * 25-80 years * individuals without active disease with previous confirmed diagnosis of covid-19 infection with negative nasopharyngeal pcr test * with characteristic chest radiographic images compatible with lung infection, particularly interstitial pneumonitis with previous unburied glass patches, cobblestone or areas of consolidation (during active disease) * sign a letter of consent under information exclusion criteria: * patients taking the following medicines: ivermectin, azithromycin, corticosteroids, colchicine, chlorine dioxide, oral anticoagulants such as acenocoumarin, apixaban, rivaroxaban; bronchodilators such as β2-agonists such as salbutamol and derivatives, as well as inhaled anticholinergics of the ipratropium bromide type and derivatives. * patients who present medical difficulty or contraindication to perform the 6 km walk test in band * patients with a history of community-acquired pneumonia, pulmonary neoplasms, heart, renal, or hepatic failure

Keywords: plasma ozone covid-19 sars cov 2 lung function
extra vascular lung water and pulmonary permeability in critically ill patients with sars-cov-2 (covid-19)

Conditions: COVID-19; Pneumonia; Acute Respiratory Distress Syndrome

Summary: acute respiratory distress syndrome (ards) is a syndromic definition of an acute lung injury with alteration of biomechanics (lower respiratory system compliance) mostly associated with increased lesional edema. increase in pulmonary vascular permeability index (pvpi) accompanied with accumulation of excess extravascular lung water (evlw) is the hallmark of ards. in routine clinical practice, the investigators measure the evlw and pvpi in ards patients, as suggested by expert's recommendations, using a transpulmonary thermodilution (tptd) technique. severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is a newly recognized illness that has spread rapidly throughout wuhan (hubei province) to other provinces in china and around the world. most critically ill patients with sars-cov-2 will present the criteria for the definition of ards. however, many of these patients have a particular form of ards with severe hypoxemia often associated with near normal respiratory system compliance. this combination is almost never seen in severe ards. thus other mechanisms (including probably vascular mechanisms), that are still poorly described, have to be involved in sars-cov-2. evlw and pvpi have never been assessed in sars-cov-2 mechanically ventilated patients. the aim of this study is to evaluate these two parameters in order to best characterize and understand the mechanisms related to sars-cov-2. based on observation of several cases in intensive care units (icu), the investigators hypothesize that there are following different sars-cov-2 patterns: 1. nearly normal compliance, low lung recruitability, normal evlw and low pvpi. 2. low compliance due to increased edema, high lung recruitability, high evlw and high pvpi.


Eligibility criteria:
inclusion criteria: * covid-19 critically ill patients * invasive mechanical ventilation exclusion criteria: * age under 18 * pregnancy * legally protected adults * contra-indication of using picco device: jugular venous thrombosis, or severe chronic femoral/iliac artery occlusive disease

Keywords: ards icu transpulmonary thermodilution extravascular lung water pulmonary vascular permeability index
rtms effect on cognitive and psychiatric dysfunction in patients with fibromyalgia

Conditions: Treatment Resistant Disorders

Summary: the aim of this work was to evaluate the effect of low frequency rtms over the right dorsolateral prefrontal area (dlpfc) on fibromyalgia patients. fibromyalgia impact questionnaire (fiq), hamilton depression and anxiety scale and different cognitive rating scales were evaluated pre-1 month post sessions and pre -post 3 months later. all eligible patients with fibromyalgia (fm) were randomized to have 20 sessions of active or sham rtms over right dlpfc. the improvement changes in groups were compared in each rating scale.

the present study was aimed to evaluate the effect of low frequency rtms over the right dorsolateral prefrontal area (dlpfc) on fibromyalgia patients. recruitment of the patients were consecutively. impact questionnaire (fiq), psychiatric and cognitive scales were evaluated before rtms. 42 eligible patients with fibromyalgia (fm) were randomly assigned to one of two groups with equal ratio. each patient received 20 sessions of active or sham rtms (1 hz, 120% of resting motor threshold with total 1200 pules /session) over right dlpfc. follow up of each patient was done blindly at , one and 3 months later with the same rating scales (fiq, hamilton depression and anxiety rating scales (hdrs and hars), montreal cognitive assessment (moca), rey auditory verbal learning test (ravlt), tower of london test (tol), the trail making and digit span tests). comparison between the changes in different rating scales were done at 1- and 3-months follow-up.

Eligibility criteria:
inclusion criteria: the diagnosis of fibromyalgia was made according to american college of rheumatology criteria with age at and older than 18 years exclusion criteria: inflammatory rheumatic disease, auto immune disease, or other painful disorders. any uncontrolled clinical disease (such as thyroid, cardiovascular, pulmonary, hematological, or renal disease) that affects cognition. pregnancy, lactation. patients have one of contra-indications for rtms (a history of seizures, brain trauma, brain surgery or intracranial hypertension, a pacemaker, or other metallic implants), past history of other neurological disorders (neurodegenerative diseases, dementia), or primary psychiatric disorders (psychosis, or major depression (17-item hamilton depression rating scale \> 23), or drug treatments that affect cognition. inability to cooperate with the questionnaire survey or the patient refuses to participate in the study.

Keywords: rtms fibromyalgia hamilton depression and anxiety scale moca dlpfc
pap systems external clinical studies (ecs)

Conditions: Obstructive Sleep Apnea

Summary: this is a pre-market study for ongoing product development aiming to explore the usability and performance of the study pap systems.

this is an open label, prospective, randomized cross over (or single arm) study for ongoing product development of new accessories for pap devices. this generic protocol provides a framework methodology for how these ongoing studies will be conducted. this protocol then is used in a number of smaller sub-studies phases, each of which will have their own sub-protocol outlining the exact specifics of the study. the studies could be run face-to-face or remotely. participants who met the inclusion/exclusion criteria will be contacted. recruitment will be done via emails. participants will be explained the details of the trial and those who wish to take part will be invited to a selected site for the first study visit. visit 1: participants will provide written informed consent. participants will be shown the pap systems and trial them for fit and comfort. participants may be asked initial questions on their first thoughts on the pap systems. if the participant and assessor are happy to proceed, the participants will use the loan pap system for trial. visit 2: after trialing the pap systems, participants will be asked to complete a questionnaire regarding the appeal, comfort, and usability of the pap system(s). depending on sub-study protocol, participants will then take the second pap system home to test. visit 3: the participant will return the loan pap system to the assessor. the participants' questionnaire responses will be reviewed. this concludes the participation in the study.

Eligibility criteria:
inclusion criteria: * participants willing to give written informed consent * participants who ≥ 18 years of age * participants being treated for osa for ≥ 3 months * participants currently using a suitable pap system(s) * participants who can trial the pap systems for up to 7 nights each additional criteria for remote studies: * participants currently using pap device compatible with airview, or with download capacity from pap machine from data cards * participants who have access to video call equipment exclusion criteria: * participants using bilevel flow generators * participants who are or may be pregnant * participants with a preexisting lung disease/ condition that would predispose them to pneumothorax (for example: copd, lung cancer; fibrosis of the lungs; recent (\< 2years) case of pneumonia or lung infection; lung injury. * participants believed to be unsuitable for inclusion by the researcher * participants who or whose bed partner has implantable medical devices which may contraindicate against masks with magnetic clips (exclusion criteria for study masks with magnetic clips only) * participants who are currently enrolled in other clinical studies
trial of efficacy and safety of pregabalin in subjects with neuropathic pain associated with lumbo-sacral radiculopathy

Conditions: Radiculopathy

Summary: trial will evaluate the efficacy and safety of pregabalin in the treatment of subjects with neuropathic pain associated with lumbo-sacral radiculopathy.


Eligibility criteria:
inclusion criteria: * pain consistent with a diagnosis of chronic lumbo-sacral radiculopathy due to spinal stenosis or disk herniation. * radicular pain must be present for at least 3 months and pain stable for at least 4 weeks. exclusion criteria: * surgery for lumbo-sacral radiculopathy within previous 6 months and/or more than one previous spinal surgery for pain-radiculopathy. * epidural injection for lumbo-sacral radiculopathy within previous 6 weeks and/or anticipated need for treatment with opioid analgesics, anti-epileptic medications or tricyclic antidepressants to alleviate pain due to lumbo-sacral radiculopathy during the course of the study.
impact of fluocinonide 0,05% in oral lichen planus

Conditions: Oral Lichen Planus

Summary: a double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of fluocinonide 0,05% and determinate the statistical significance of the outcome variables. oral cavity lichen is a chronic inflammatory condition affecting the mucosa of the oral cavity , which significantly reduces the quality of life of affected individuals.

a double-blind placebo-controlled study was conducted to evaluate the clinical efficacy of fluocinonide 0.05% oral gel and determine the statistical significance of outcome variables. 20 patients with oral lichen planus were divided by a randomization system, into two groups: case group treated with fluocinonide 0.05% oral gel and applied to oral lesions 2 times a day for 1 month and a placebo group as a control group; with 2 months of follow-up.

Eligibility criteria:
inclusion criteria: * clinical and histologic diagnosis of lichen planus orale; * presence of symptoms related to lichen planus orale; * clinical follow-up period of at least 12 weeks; * acceptance of informed consent exclusion criteria: * state of pregnancy or lactation; h * histologic signs of dysplasia; * medications that induce a lichenoid response (ace inhibitors, β-blockers, etc.); * presence of amalgam fillings in the vicinity of lesions; * treatment of oral lichen in the previous 6 months from the start of the program; * presence of extraoral lesions (genital, skin, etc.); * diabetes being treated with oral hypoglycemic drugs; * history of previous immunodeficiency; * hiv seropositivity; * previous allogeneic bone marrow transplantation; * diagnosis of les or other autoimmune disease
effects of intermittent running on metabolic health

Conditions: Glucose Control; Metabolic Regulation; Energy Expenditure

Summary: the purpose of this study is to investigate the suitability of intermittent exercise of long and short intervals at lower intensities than hiie on energy expenditure during and post-exercise compared to mice, as well as determine whether similar or greater effects can be achieved for glycemic control in recreationally active adults.

the same procedure will be repeated for all trials: participants will be asked to perform 4 trials in a randomized-crossover design \[moderate-intensity continuous running (mice: 60% v̇o2max), 5-minute interval running (5min; 50% and 70% v̇o2max), 2-minute interval running (2min; 50% and 70% v̇o2max), or a control with no exercise (con)\]. all trials will be separated by at least 4 days wash-out and less than 14 days between trials to ensure complete rest. sensors for measuring muscle oxygen (10 cm proximal to the mid-patella, and 2 cm lateral) will be placed on the rectus femoris muscle and 15 min resting metabolic rate was measured. a bilateral antecubital venous line for blood sampling will be inserted by a nurse. after baseline measurements, participants warm-up for 3 minutes with fixed walking intensity (i.e., 5 km/h) followed by 40 minutes running. immediately after the running, participants return to a seated position for 30 minutes post-exercise measurements (epoc). after the 30 minutes measurement, 5-minutes was given for participants to go to the bathroom and drink 100ml water, whereafter a standard 120-minutes oral glucose tolerance test (ogtt) is conducted (75g glucose dose with 50ml of water). the timer will be started at the first sip. during the epoc and resting metabolic rate (rmr) measurement participants will sit in a comfortable position and need to limit fidgeting, thus allowed only to watch tv or videos on their phone. during the ogtt, participants can do any calm activity such as watching tv, reading, working on the laptop, but no physical activity. participants will be wheeled to the bathroom if needed.

Eligibility criteria:
inclusion criteria: * healthy recreationally active men * bmi between 18.5-27 kg/m2 * aged between 20 to 45 years * regular exercise (3 times per week and longer than 3 months) with cardio exercise longer than 30 minutes at least once a week * weight stable for more than 3 months (no change in weight +/- 3%) * non-shift workers and sleep at least 6.5-9 hours for the past 3 months * non-smoker exclusion criteria: * having any cardiovascular, metabolic or pulmonary disease (angina pectoris or uncontrolled arrhythmias) * suffering from infectious contagious diseases, * using medications that could affect metabolic responses (including anti-inflammatory medications) * smoking * heavy alcohol intake (more than 4 drinks on any day or more than 14 drinks a week). * undergoing special diets (e.g., intermittent fasting and/or ketogenic diets)

Keywords: intermittent running ogtt energy expenditure glucose control
regional versus general anesthesia for promoting independence after hip fracture

Conditions: Hip Fractures

Summary: the purpose of this study is to find out if two types of standard care anesthesia are the same or if one is better for people who have hip fractures.

hip fracture is a clinical condition that involves a break in the femur (hip bone) near where it attaches to the pelvis. hip fractures occur more than 300,000 times each year in the us and over 1.6 million times each year worldwide. over 90% of hip fractures occur in individuals aged 50 or older, most commonly resulting from low-energy traumatic injuries, such as falls from standing in the context of established osteoporosis, chronic illness, or disability. surgical treatment, via fixation of the fractured bone or partial or total replacement of the hip joint, is indicated for all types of hip fractures and approximately 95% of hip fracture patients undergo surgery. no evidence-based interventions now exist to improve functional outcomes after hip fracture surgery beyond the immediate postoperative period. nearly all hip fracture patients require orthopedic surgery and anesthesia, making the anesthetic care episode a major opportunity to impact outcomes. spinal and general anesthesia represent the two standard care approaches to anesthesia for hip fracture surgery. basic and clinical research has identified multiple plausible mechanisms by which spinal anesthesia may improve outcomes after hip fracture; nonetheless, major guidelines and systematic reviews have identified key evidence gaps and anesthesia care for hip fracture varies markedly in practice. while spinal and general anesthesia for hip fracture have been previously compared in retrospective studies and small randomized trials, much of the available prospective trial data is old and may not be reflective of current clinical practice. regain will be the first pragmatic multicenter prospective randomized trial of spinal versus general anesthesia for hip fracture surgery designed to evaluate the association of anesthesia technique with functional recovery after hip fracture. as such, it will fill critical evidence gaps to inform policy and practice. approximately 2,424 subjects will be enrolled (i.e. informed consent for participation will be obtained) in order to yield approximately 1,600 randomized patients. this estimate is based on an assumption that one in three patients (33%) who undergo consent prior to surgery will not be randomized on the day of surgery due to active clinical issues, timing of medication dosing, clinical assessments by treating physicians or the site clinical director or their designate, or patient withdrawal of consent.

Eligibility criteria:
inclusion criteria: * clinically or radiographically diagnosed intracapsular or extracapsular hip fracture * planned surgical treatment via hemiarthroplasty, total hip arthroplasty or appropriate fixation procedure * ability to walk 10 feet or across a room without human assistance before fracture exclusion criteria: * planned concurrent surgery not amenable to spinal anesthesia * absolute contraindications to spinal anesthesia * periprosthetic fracture